The Japan Times - GSK reports improved outlook despite US drug tariffs

EUR -
AED 4.042864
AFN 71.555478
ALL 90.626386
AMD 396.789587
ANG 1.970962
AOA 1010.579203
ARS 1699.438636
AUD 1.630164
AWG 1.981527
AZN 1.870698
BAM 1.953118
BBD 2.223267
BDT 137.291487
BGN 1.952322
BHD 0.416432
BIF 3314.708844
BMD 1.100848
BND 1.421342
BOB 12.887305
BRL 6.26559
BSD 1.103794
BTN 103.970712
BWP 15.428045
BYN 3.306989
BYR 21576.629451
BZD 2.220072
CAD 1.572551
CDF 2548.464071
CHF 0.925048
CLF 0.027971
CLP 1100.859145
CNY 7.344586
CNH 7.340182
COP 3651.084949
CRC 494.62533
CUC 1.100848
CUP 26.491625
CVE 110.114304
CZK 24.43114
DJF 196.561889
DKK 7.475795
DOP 67.148409
DZD 150.83203
EGP 59.060739
ERN 16.512727
ETB 181.173679
FJD 2.510041
FKP 0.832855
GBP 0.834498
GEL 2.851402
GGP 0.832855
GHS 12.942288
GIP 0.832855
GMD 81.462736
GNF 9779.749248
GTQ 8.438452
GYD 230.933957
HKD 8.637758
HNL 29.682648
HRK 7.520958
HTG 144.75387
HUF 364.714942
IDR 20106.996782
ILS 3.546823
IMP 0.832855
INR 103.392071
IQD 1673.402276
IRR 2106734.940616
ISK 136.592545
JEP 0.832855
JMD 174.412893
JOD 0.780549
JPY 175.638717
KES 143.164967
KGS 96.268533
KHR 4534.855646
KMF 492.079488
KPW 990.763983
KRW 1469.115521
KWD 0.342925
KYD 0.919837
KZT 492.014422
LAK 24846.995814
LBP 98848.170975
LKR 367.135891
LRD 187.651486
LSL 18.660862
LTL 3.25052
LVL 0.665892
LYD 7.115295
MAD 10.93888
MDL 20.05056
MGA 5015.159317
MKD 61.538484
MMK 2311.306937
MNT 3967.489416
MOP 8.920851
MRU 44.642108
MUR 52.631293
MVR 16.955842
MWK 1914.08918
MXN 20.449047
MYR 4.506766
MZN 70.331926
NAD 18.660777
NGN 1481.49971
NIO 40.624957
NOK 10.571002
NPR 166.354093
NZD 1.995937
OMR 0.423285
PAB 1.103784
PEN 3.755843
PGK 5.037152
PHP 70.412485
PKR 305.237156
PLN 4.404374
PYG 6850.655697
QAR 4.023893
RON 5.349685
RSD 117.601459
RUB 90.875482
RWF 1633.079894
SAR 4.142649
SBD 8.914337
SCR 15.159395
SDG 662.159924
SEK 11.09986
SGD 1.419164
SHP 0.828921
SLE 25.374813
SLL 23084.245426
SOS 630.842395
SRD 41.27043
STD 22785.340133
STN 24.466738
SVC 9.658738
SYP 14313.231806
SZL 18.654454
THB 37.34085
TJS 10.182672
TMT 3.85297
TND 3.327346
TOP 2.650579
TRY 55.4744
TTD 7.492712
TWD 36.254133
TZS 2918.874306
UAH 50.186545
UGX 4558.761139
USD 1.100848
UYU 44.738367
UZS 13273.773979
VES 1004.941699
VND 28362.259244
VUV 132.893978
WST 3.094027
XAF 655.957
XAG 0.023115
XAU 0.000284473133
XCD 2.975098
XCG 1.989368
XDR 0.778357
XOF 655.957
XPF 119.331742
YER 260.406273
ZAR 18.663884
ZMK 9908.960466
ZMW 22.568217
ZWL 354.472749
SSP 6544.963616
MXV 2.294661
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

GSK reports improved outlook despite US drug tariffs
GSK reports improved outlook despite US drug tariffs / Photo: JUSTIN TALLIS - AFP

GSK reports improved outlook despite US drug tariffs

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter.

Text size:

GSK, which makes medicines in the European Union as well as in Britain and the United States, said its guidance took into account "the European tariffs indicated this week".

The EU-US trade deal reached at the weekend set a 15 percent tariff on most European Union goods imported into the United States, though it is thought that Washington could still take steps that would see medicines face a higher levy.

Despite the backdrop, GSK chief executive Emma Walmsley said the group expected to be "towards the top end of" its financial guidance for 2025 and remained "confident" over the longer term.

"GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology and inflammation, oncology and HIV," she added in a statement.

Addressing an online press conference later Wednesday, Walmsley said GSK was "very well positioned" to increasingly supply the United States, its "number one priority market", from within the country.

"Our overall planned investment in the US is in the tens of billions of dollars over the next five years," she added.

The company said net profit jumped 23 percent to £1.44 billion ($1.92 billion) in the three months to the end of June compared with the second quarter in 2024.

Group sales increased one percent to £8 billion, helped by a 36 percent increase in cancer treatments that offset falls for other drugs, including for influenza.

Just over half of total revenue was earned in the US market during the second quarter.

"The prognosis for GSK is looking positive," said Derren Nathan, head of equity research at Hargreaves Lansdown.

"It hasn't let itself get too distracted by tariff uncertainty, with both second-quarter sales and earnings coming in ahead of market forecasts," he said.

GSK shares advanced 1.0 percent in afternoon deals on the London stock exchange, bucking a downward trend on the benchmark FTSE 100 index.

Y.Hara--JT